WO2009126335A3 - Ant2 inhibitor compounds and methods of use thereof - Google Patents

Ant2 inhibitor compounds and methods of use thereof Download PDF

Info

Publication number
WO2009126335A3
WO2009126335A3 PCT/US2009/002295 US2009002295W WO2009126335A3 WO 2009126335 A3 WO2009126335 A3 WO 2009126335A3 US 2009002295 W US2009002295 W US 2009002295W WO 2009126335 A3 WO2009126335 A3 WO 2009126335A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
ant2
inhibitor compounds
diseases
cell proliferation
Prior art date
Application number
PCT/US2009/002295
Other languages
French (fr)
Other versions
WO2009126335A2 (en
Inventor
Naohiro Terada
David A. Ostrov
Original Assignee
University Of Florida Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida Research Foundation, Inc. filed Critical University Of Florida Research Foundation, Inc.
Publication of WO2009126335A2 publication Critical patent/WO2009126335A2/en
Publication of WO2009126335A3 publication Critical patent/WO2009126335A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods of treating cell proliferation related disorders or diseases, such as cancer. The invention further relates to pharmaceutical compositions for treating cell proliferation related disorders or diseases.
PCT/US2009/002295 2008-04-08 2009-04-08 Ant2 inhibitor compounds and methods of use thereof WO2009126335A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12352408P 2008-04-08 2008-04-08
US61/123,524 2008-04-08

Publications (2)

Publication Number Publication Date
WO2009126335A2 WO2009126335A2 (en) 2009-10-15
WO2009126335A3 true WO2009126335A3 (en) 2010-01-14

Family

ID=41162476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/002295 WO2009126335A2 (en) 2008-04-08 2009-04-08 Ant2 inhibitor compounds and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2009126335A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120095263A (en) * 2011-02-18 2012-08-28 주식회사 바이오인프라 Method for treating breast cancer by decreasing the expression of adenine nucleotide translocator 2 mrna
US9795584B2 (en) * 2013-07-30 2017-10-24 University Of South Florida Treating an atypical protein kinase C enzyme abnormality
WO2015196121A2 (en) * 2014-06-19 2015-12-23 University Of South Florida Method of treating ovarian cancer using a pkc inhibitor
CN112516317B (en) * 2020-12-10 2021-12-17 暨南大学附属第一医院（广州华侨医院） Pharmaceutical composition for preventing and treating cancer and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088078A2 (en) * 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088078A2 (en) * 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated INHIBITORS OF GSK-3 AND CRYSTAL STRUCTURES OF GSK-3β PROTEIN AND PROTEIN COMPLEXES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRAS MORGANE LE ET AL.: "Chemosensitization by Knockdown of Adenine Nucleotide Translocase-2", CANCER RES, vol. 66, no. 18, 2006, pages 9143 - 9152 *
CHEVROLLIER ARNAUD ET AL.: "ANT2 Isoform Required for Cancer Cell Glycolysis", JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, vol. 37, no. 5, 2005, pages 307 - 316 *
WELCH KAREN T. ET AL.: "Discovery of non-carbohydrate inhibitors of aminoglycoside modifying enzymes", BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 13, 2005, pages 6252 - 6263 *

Also Published As

Publication number Publication date
WO2009126335A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
WO2009155001A3 (en) Wnt protein signalling inhibitors
WO2013163190A8 (en) Dna-pk inhibitors
WO2010011296A3 (en) Deacetylase inhibitors and uses thereof
WO2010014253A3 (en) Ant4 inhibitor compounds and methods of use thereof
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009011850A3 (en) Novel therapeutic compounds
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
WO2006071960A3 (en) Compositions and methods of treating cell proliferation disorders
WO2007123892A3 (en) Raf inhibitors and their uses
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IN2012DN03883A (en)
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
MX2013001970A (en) Pyrrolopyrimidine compounds and uses thereof.
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2011082270A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09729617

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09729617

Country of ref document: EP

Kind code of ref document: A2